Duloxetine-tranylcypromine

From Psychiatrienet
Revision as of 16:49, 11 May 2009 by Walter (talk | contribs)
Jump to: navigation, search
Duloxetine
Type Antidepressant
Group SNRI
links
Medscape Duloxetine
PubChem 60835
PubMed Duloxetine
Kompas (Dutch) Duloxetine
Wikipedia Duloxetine
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine

Switch medication from duloxetine to tranylcypromine.[1] [2]

Nietinrijdenbord.png Stop duloxetine
  • Day 0: gradually reduce dosage of duloxetine to a maximum of 30 mg/ day. When a dosage of 30 mg/day is reached, stop administration.
Eenrichtingbord.png Start tranylcypromine

A wash-out period of two weeks is necessary.

  • Day 1-13: wash-out period
  • Day 14-21: start tranylcypromine 20 mg/day.
  • Day 22: increase dosage of tranylcypromine if necessary.
Infobord.png More information
  • By considering a wash-out period of one week (5 times the elimination time of duloxetine and its metabolites) it is assured that all duloxetine has left the body and no drug interactions occur.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.